CannAssist International Corp. (OTCQB: CNSC), owner of Xceptor Labs, is a biotechnological pharmaceutical and wellness company marketing the Xceptol consumer brand.
CannAssist, a Delaware corporation, was established in May 2017 and is headquartered in San Diego County, California.
2018 Farm Bill and CBD Market Size
Signed into law in December 2018, the Agriculture Improvement Act of 2018 (2018 Farm Bill) removed hemp from its classification as a Schedule I drug under the Controlled Substances Act of 1970.
There are over 100 known cannabinoids within the hemp plant. The two most commonly utilized cannabinoids are THC (tetrahydrocannabinol) and CBD (cannabidiol). Cannabinoids have been shown to affect the endocannabinoid system within the human body, which is why CBD has demonstrated effectiveness as a therapeutic option when delivered through the right absorption avenues.
The 2018 Farm Bill is expected to have a sustained impact on the growth of the cannabidiol market and related sectors. In 2018, the global cannabidiol market was valued at $4.6 billion, and it’s expected to increase almost sixfold by 2025, reaching $23.6 billion (https://ibn.fm/PL6PO).
This growth is expected to provide multiple opportunities to CannAssist and its high-quality, high-performance brands, including products currently under development. Based on current revenue from licensing agreements, retail sales and the Xceptol brand’s international distribution, the company expects to reach first-year sales of $5 million. With additional products in the pipeline and an unwavering commitment to quality and effectiveness, the company expects to see steady sales growth in the years ahead.
Xceptor Labs is an R&D and raw material manufacturing company that partners with TakaUSA, in Coppell, Texas, for contract manufacturing and production services.
Xceptor Labs’ technology, CiBiDinol, is formulated using a proprietary process developed by CannAssist Founder Mark Palumbo. It is specifically designed to address many critical issues with oil-soluble CBD molecules, including delivery, bioavailability and short shelf-life. This technology provides the basis for Xceptor Labs and Xceptol consumer products.
CiBiDinol is believed to provide CBD in a format that is more in line with the body’s natural bioactivity. The company’s proprietary processes are used to combine CBD molecules with penetration enhancing cyclodextrin, effectively modifying the CBD molecule’s surface and rendering it water dispersible. This technology enhances absorption through the skin and gut.
The company believes that CBD products created using its CiBiDinol technology offer more predictable potency and enable reduced dosage requirements. This technology clears the way for a wide variety of products, including many oil-soluble active ingredients and highly effective consumer product applications.
Third-party testing has confirmed that products made with CiBiDinol demonstrate a 400 percent increase in skin penetration as compared to regular CBD in oil carriers alone, as well as a 300 percent higher absorption rate in the gut. The company believes that the results indicate that the amount of CBD needed to achieve targeted endpoints can be significantly lower, resulting in lower costs for manufacturers and consumers with little to no side effects.
“Oversight of manufacturing and third-party testing of this ingredient produced consumer products designed to provide clinicians and consumers safe, effective, and affordable treatment options to address their health and wellness concerns,” Palumbo said in a news release.
CiBiDinol is currently being evaluated for safety by the National Science Foundation for Global Recognition and has been submitted to the FDA’s bulk drug substance program. The company is developing a commerce pathway in each state’s pharmaceutical distribution network through the National Board of Pharmacies. The company aims to capture increasing market share through product extensions and advancements by seeking critical third-party analysis and physician feedback regarding its proprietary technology’s attributes. Xceptor Labs intends to offer licensing arrangements for brand-consumer companies.
CiBiDinol technology is the foundation for Xceptor Labs and the Xceptol line of products, including topical creams, capsules, tinctures and pet drops. The Xceptol line began launching its products in September 2020, and it currently has five National Drug Code topical pain creams utilizing ingredients registered with the FDA.
Xceptol products will be sold online, through Range Me, as well as through national and international retail and pharmaceutical distributors. Marketing for Xceptol products is planned through multiple social media campaigns including using celebrities and former athletes associated with Freedman Sports Promotional Relations.
Xceptol is establishing sales channels in North America, Central America, South America, South Africa, the EU, the UK and the Philippines.
Mark Palumbo, CEO and Founder, is an entrepreneur, scientist and executive with over 30 years in the health care, laboratory and manufacturing industries. His entrepreneurial endeavors include a successful personal care industry distribution company, a currently owned and operated tissue culture laboratory and Xceptor Labs, now part of CannAssist International.
Marla Palumbo, President, is a health care professional and registered nurse with over 30 years of experience in the industry. She handles sales, patient advocacy, patient care and general management. Marla Palumbo has effectively developed and grown a personal care distribution company with significant year over year increases in sales. Her management and organization skills were instrumental in the early development of Xceptor Labs, leading to its CannAssist International public company status.
Dr. Rahul Dixit, MD, Medical Director, is a doctor of gastroenterology at Providence St. John’s Medical Center in Santa Monica, California. He was part of a double fellowship with the University of Miami in Gastroenterology and Hepatology/Liver Transplant at Johns Hopkins Hospital. He has over 20 years of experience with cannabis and hemp-related products.
Takako McGowan, Managing Director, Founding Member and Owner of TakaUSA, brings 40 years of experience in manufacturing and consumer product research & development to the CannAssist team.
Camron Elizabeth, Managing Director-Sales and Marketing, is an entrepreneur and leader who has brought immense success to the companies with whom she has worked. As Founder and CEO of Platinum Pack, Elizabeth was responsible for all aspects of its success in bringing products from concept to completion and successful sell-through on the retailer’s shelf. She has been in the beauty industry for over 40 years.
Benjamin Perlstein, VP of Operations, has been a part of the health care and business development field for over 25 years. As a surgical technologist, he has experience as a clinical application specialist and materials manager.
Braden Traub, Director of Marketing and Customer Development, is an entrepreneur and business owner with 10 years of experience in the health and fitness industries. Traub also has skills and experience as a tax resolutionist and legal document preparer.
Safe Harbor for Forward-Looking Statements
Forward-looking statements are inherently subject to risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, the following: the timing and nature of any capital raising transactions; the Company’s ability to offer products and services for use by customers in existing and new markets; the Company’s ability to deliver in a timely fashion and to its customers’ satisfaction the products purchased; the risk of competition; its ability to find, recruit and retain personnel with knowledge and experience in selling products and services in existing and new markets; its ability to manage growth; and general market, economic and business conditions. Additional factors that could cause actual results to differ materially from those anticipated by the Company’s forward-looking statements are under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in its Annual Report on Form 10-K for the fiscal year 2019 and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, all filed with the Securities and Exchange Commission. Forward-looking statements are made as of the date hereof, and the Company expressly disclaim any obligation or undertaking to update forward-looking statements.
- In July 2020, CannAssist International became among the first U.S.-based CBD companies to have its securities listed for trading onto a U.S. public capital market.
- Xceptor Labs uses proprietary technology to create CBD products that it believes have better absorption than currently marketed oil-based products.
- The company currently has five creams that utilize ingredients with National Drug Codes that are registered with the FDA.
- The company’s Xceptol line of topical pain cream products, formulated using its proprietary CiBiDinol technology, was launched in September 2020. The company has since added capsules and, very soon, tinctures and pet drops.
- The company’s marketing structure for Xceptol includes social media campaigns featuring celebrities and former athletes represented through Freedman Sports Promotional Relations.
- CannAssist is currently targeting North America, Central America, South America, South Africa, the EU, the UK and the Philippines as viable product markets.
- Strategic partnerships have already collaborated in sourcing, manufacturing, processing, laboratory, distribution, public relations and legal representation.
- The global market for cannabidiol is expanding steadily and is forecast to reach $23.6 billion in 2025.